摘要
二肽基肽酶4(DPP-4)抑制剂是一类具有新型作用机制的2型糖尿病治疗药物。与目前常用的口服降糖药物相比,DPP-4抑制剂具有改善胰岛α及β细胞功能、改善胰岛素抵抗等作用,是目前2型糖尿病药物研究的热点。阿格列汀作为一种新上市的DPP-4抑制剂,在单用或与其他降糖药联合应用时控制血糖疗效较好,且不增加低血糖、心血管风险,也不增加患者的体质量。
Dipeptidyl peptidase-4（DPP4） inhibitor is a kind of drug for treating type 2 diabetes with new action mechanism. Compared with the commonly used oral medications, DDP-4 has the function that improves pancreatic island a and β ceil,insulin resistance and so on. Nowadays,it is a hotspot of the type 2 diabetes medication. Being a new type of anti-hyperglucaemia, alogliptin can effectively control blood glucose as monotherapy or in combination with other antidiabetic drugs, with low risk of cardiovascular disease and hypoglycemia,and does not increase body weight. Here reviews the recent clinical research advances and safety.
出处
《医学综述》
2015年第24期4523-4525,共3页
Medical Recapitulate
